Treating cancer by inhibiting expression of olfm4, sp5, tob1, arid1a, fbn1 or hat1
AssigneesSingapore Health Services Pte Ltd, National University of Singapore
InventorsPatrick Tan, Hue Kian Oh
Life of this patent
Estimating the term…
Abstract
The present invention in one aspect relates to a method for treating cancer or enhancing a cancer treatment, the method comprising inhibiting the expression of an oligonucleotide encoding for a protein selected from the group consisting of OLFM4, SP5, TOB1, ARID1A, FBN1 and HAT1, by administering to a mammal in need of cancer treatment an effective amount of at least one silencing oligonucleotide comprising a binding motif for binding to the oligonucleotide encoding for a protein.
Claims33
A method for treating cancer or enhancing a cancer treatment, the method comprising inhibiting the expression of an oligonucleotide encoding for a protein selected from the group consisting of OLFM4, SP5, TOB1, ARID1A, FBN1 and HAT1, by administering to a mammal in need of cancer treatment an effective amount of at least one silencing oligonucleotide comprising a binding motif with a core nucleotide sequence of UCCUGUAC, or at least one silencing oligonucleotide targeting the 3′ untranslated region of the oligonucleotide encoding for a protein selected from the group consisting of OLFM4, SP5, TOB1, ARID1A, FBN1 and HAT 1.
A method of inducing apoptosis in a mammal in need thereof, the method comprising administering to the mammal an effective amount of at least one silencing oligonucleotide comprising a binding motif of with a core nucleotide sequence of UCCUGUAC to bind and thereby inhibit an anti-apoptotic protein in the mammal.
A method of screening for cancer, the method comprising screening for a silencing oligonucleotide comprising a binding motif with a core nucleotide sequence of UCCUGUAC or an oligonucleotide encoding for a protein including a matching nucleotide sequence being complementary to the nucleotide sequence of UCCUGUAC.
Dependencies are inferred from the claim text.